The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
Open accessAbstract
BACKGROUND: Planning for outbreaks of influenza is a high priority public health issue for national governments. Neuraminidase inhibitors (NIs) are thought to help reduce the symptoms of influenza with several possible mechanisms proposed. NIs have been stockpiled with a view to their widespread use in the event of a pandemic. However, the evidence base for this class of agents remains a source of debate. In a previous review we have documented substantial risks of publication bias of trials of NIs for influenza (60% of patient data from phase III treatment trials of oseltamivir have never been published) and reporting bias in the published trials. Our confidence in the conclusions of previous versions of this review has been subsequently undermined. Since we have become aware of a large number of unpublished trials of NIs in the management of influenza, this review updates and merges existing reviews in this area. OBJECTIVES: To review clinical study reports of placebo-controlled randomised trials, regulatory comments and reviews ('regulatory information') of the effects of the NIs oseltamivir and zanamivir for influenza in all age groups and appraise trial programmes, rather than single studies.Clinical study reports are very detailed, unpublished clinical trial data containing in-depth descriptions of protocol rationale, methods analysis plans, trial results and organisational documents (such as contracts). A series of clinical studies designed and conducted by one sponsor represents a trial programme of a drug indication (for example treatment of influenza). SEARCH METHODS: We searched trial registries, cross-referencing published and unpublished sources and corresponded with manufacturers and regulators. We searched the archives of the US Food and Drug Administration (FDA) and European and Japanese regulators. The evidence in this review reflects searches to obtain relevant information up to 12 April 2011. SELECTION CRITERIA: We included regulatory information based on assessments of randomised controlled trials (RCTs) conducted in people of any age who had either confirmed or suspected influenza, or who had been exposed to influenza in the local community or place of residence. We included information which had been made available by our deadline. DATA COLLECTION AND ANALYSIS: We indexed regulatory information in two purpose-built instruments and reconstructed trials using CONSORT statement-based templates. To progress to Stage 2 (full analysis) we sought manufacturer explanations of discrepancies in the data. GlaxoSmithKline (GSK) offered us individual patient data and responded to our queries, but Roche did not provide us with complete clinical study reports. In Stage 2 we intended to analyse trials with validated data (i.e. assuming our validation questions aimed at clarifying omissions and discrepancies were resolved). No studies progressed to Stage 2. We carried out analyses of the effects of oseltamivir on time to first alleviation of symptoms and hospitalisations using the intention-to-treat (ITT) population and tested five hypotheses generated post-protocol publication. MAIN RESULTS: We included and analysed data from 25 studies (15 oseltamivir and 10 zanamivir studies). We could not use data from a further 42 studies due to insufficient information or unresolved discrepancies in their data. The included trials were predominantly conducted in adults during influenza seasons in both hemispheres. A small number of studies were conducted in older people residing in care homes and in people with underlying respiratory diseases. The studies had adequate randomisation and blinding procedures, but imbalances in the analysis populations available (ITT influenza-infected) left many of the studies at risk of attrition bias. All the studies were sponsored by manufacturers of NIs. Time to first alleviation of symptoms in people with influenza-like illness symptoms (i.e. ITT population) was a median of 160 hours (range 125 to 192 hours) in the placebo groups and oseltamivir shortened this by around 21 hours (95% confidence interval (CI) -29.5 to -12.9 hours, P < 0.001; five studies) but there was no evidence of effect on hospitalisations based on seven studies with a median placebo group event rate of 0.84% (range 0% to 11%): odds ratio (OR) 0.95; 95% CI 0.57 to 1.61, P = 0.86). These results are based on the comprehensive ITT population data and are unlikely to be biased. A post-protocol analysis showed that participants randomised to oseltamivir in treatment trials had a reduced odds being diagnosed with influenza (OR 0.83; 95% CI 0.73 to 0.94, P = 0.003; eight studies), probably due to an altered antibody response. Zanamivir trials showed no evidence of this. Due to limitations in the design, conduct and reporting of the trial programme, the data available to us lacked sufficient detail to credibly assess a possible effect of oseltamivir on complications and viral transmission. We postponed analysis of
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Dooley, L., Hama, R., & Heneghan, C. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001265.pub2 · Cited by 226
Self-citationRetractedCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
(2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,011
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
(2008) · Cited by 3,790
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Harpaz, R., Ortega‐Sanchez, I. R., & Seward, J. F. (2008) · Cited by 1,303
Avian Influenza A (H5N1) Infection in Humans
(2005) · New England Journal of Medicine · doi:10.1056/nejmra052211 · Cited by 1,285
Research works printed but not linked: 6
- Ambrozaitis, 2001, Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population, Journal of the American Geriatrics Society, 49, 130
- 201, Influenza activity - United States and worldwide, June 13-September 25, 2010, Morbidity and Mortality Weekly Report, 59, 1270
- The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) M4: the common technical document http://www.ich.org/products/ctd.html
- Jack, Cost of WHO's proposed purchase of flu drugs questioned, Financial Times (Asia Ed1), 2
- Lefebvre, 2011, Chapter 6: Searching for studies
- Smith, 2009, Point-by-point response from Roche to BMJ questions, BMJ, 339, b5374, 10.1136/bmj.b5374 · doi:10.1136/bmj.b5374
Cited by
Increasing value and reducing waste: addressing inaccessible research
Chan, A.-W., Song, F., Vickers, A., Jefferson, T., Dickersin, K., Gøtzsche, P. C., Krumholz, H. M., Ghersi, D., & van der Worp, H. B. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62296-5 · Cited by 887
Self-citationUyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Fry, A. M., Gravenstein, S., Hayden, F. G., Harper, S. A., Hirshon, J. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy866 · Cited by 795
Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment
Griffiths, C., Drews, S. J., & Marchant, D. J. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-16 · Cited by 586
Schilder, A. G. M., Chonmaitree, T., Cripps, A. W., Rosenfeld, R. M., Casselbrant, M. L., Haggard, M. P., & Venekamp, R. P. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.63 · Cited by 577
Prina, E., Ranzani, O. T., & Torres, A. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60733-4 · Cited by 516
Influenza virus-induced lung injury: pathogenesis and implications for treatment
Herold, S., Becker, C., Ridge, K. M., & Budinger, G. R. S. (2015) · European Respiratory Journal · doi:10.1183/09031936.00186214 · Cited by 503
Impact of Obesity on Influenza A Virus Pathogenesis, Immune Response, and Evolution
Honce, R., & Schultz-Cherry, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01071 · Cited by 457
Jefferson, T., Jones, M., Doshi, P., Spencer, E. A., Onakpoya, I., & Heneghan, C. J. (2014) · BMJ · doi:10.1136/bmj.g2545 · Cited by 447
Self-citationUyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Fry, A. M., Gravenstein, S., Hayden, F. G., Harper, S. A., Hirshon, J. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy874 · Cited by 413
Neuraminidase inhibitors for preventing and treating influenza in adults and children
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Hama, R., Thompson, M. J., Spencer, E. A., Onakpoya, I. J., Mahtani, K. R., Nunan, D., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008965.pub4 · Cited by 382
Self-citationNon-publication of large randomized clinical trials: cross sectional analysis
Jones, C. W., Handler, L., Crowell, K. E., Keil, L. G., Weaver, M. A., & Platts-Mills, T. F. (2013) · BMJ · doi:10.1136/bmj.f6104 · Cited by 350
Hartling, L., Featherstone, R., Nuspl, M., Shave, K., Dryden, D. M., & Vandermeer, B. (2017) · BMC Medical Research Methodology · doi:10.1186/s12874-017-0347-z · Cited by 324
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Hama, R., Thompson, M., Spencer, E. A., Onakpoya, I., Mahtani, K. R., Nunan, D. N., et al. (2014) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.20141324t2 · Cited by 319
Self-citationPhysical interventions to interrupt or reduce the spread of respiratory viruses
Jefferson, T., Del Mar, C. B., Dooley, L., Ferroni, E., Al-Ansary, L. A., Bawazeer, G. A., van Driel, M. L., Jones, M. A., Thorning, S., Beller, E. M., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006207.pub5 · Cited by 318
Self-citationImproving data transparency in clinical trials using blockchain smart contracts
Nugent, T., Upton, D., & Cimpoesu, M. (2016) · F1000Research · doi:10.12688/f1000research.9756.1 · Cited by 309
Hsu, J., Santesso, N., Mustafa, R., Brozek, J., Chen, Y. L., Hopkins, J. P., Cheung, A., Hovhannisyan, G., Ivanova, L., Flottorp, S. A., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-7-201204030-00411 · Cited by 307
Physical interventions to interrupt or reduce the spread of respiratory viruses
Jefferson, T., Dooley, L., Ferroni, E., Al-Ansary, L. A., van Driel, M. L., Bawazeer, G. A., Jones, M. A., Hoffmann, T. C., Clark, J., Beller, E. M., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006207.pub6 · Cited by 291
Self-citationRemdesivir against COVID-19 and Other Viral Diseases
Malin, J. J., Suárez, I., Priesner, V., Fätkenheuer, G., & Rybniker, J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00162-20 · Cited by 295
Real-time numerical forecast of global epidemic spreading: case study of 2009 A/H1N1pdm
Tizzoni, M., Bajardi, P., Poletto, C., Ramasco, J. J., Balcan, D., Gonçalves, B., Perra, N., Colizza, V., & Vespignani, A. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-165 · Cited by 293
The evolution and future of influenza pandemic preparedness
Harrington, W. N., Kackos, C. M., & Webby, R. J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00603-0 · Cited by 279
Bronchiectasis in children: diagnosis and treatment
Chang, A. B., Bush, A., & Grimwood, K. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31554-x · Cited by 276
Publication bias: what is it? How do we measure it? How do we avoid it?
Song, F., Hooper, & Loke, Y. (2013) · Open Access Journal of Clinical Trials · doi:10.2147/oajct.s34419 · Cited by 275
Corticosteroids as adjunctive therapy in the treatment of influenza
Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J., & Lim, W. S. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010406.pub2 · Cited by 264
Rathbone, J., Hoffmann, T., & Glasziou, P. (2015) · Systematic Reviews · doi:10.1186/s13643-015-0067-6 · Cited by 184
Saunders-Hastings, P., Crispo, J. A. G., Sikora, L., & Krewski, D. (2017) · Epidemics · doi:10.1016/j.epidem.2017.04.003 · Cited by 183
Popkin, D. L., Zilka, S., Dimaano, M., Fujioka, H., Rackley, C., Salata, R., Griffith, A., Mukherjee, P. K., Ghannoum, M. A., & Esper, F. (2017) · Pathogens and Immunity · doi:10.20411/pai.v2i2.200 · Cited by 123
Pizzorno, A., Padey, B., Terrier, O., & Rosa-Calatrava, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00531 · Cited by 122
Baudard, M., Yavchitz, A., Ravaud, P., Perrodeau, E., & Boutron, I. (2017) · BMJ · doi:10.1136/bmj.j448 · Cited by 107
Blood pressure lowering efficacy of renin inhibitors for primary hypertension
Musini, V. M., Lawrence, K. A., Fortin, P. M., Bassett, K., & Wright, J. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007066.pub3 · Cited by 98
Whaley, P., Aiassa, E., Beausoleil, C., Beronius, A., Bilotta, G., Boobis, A., de Vries, R., Hanberg, A., Hoffmann, S., Hunt, N., et al. (2020) · Environment International · doi:10.1016/j.envint.2020.105926 · Cited by 91
Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events
Mayo-Wilson, E., Fusco, N., Li, T., Hong, H., Canner, J. K., Dickersin, K., Bertizzolo, L., Cowley, T., Doshi, P., Ehmsen, J., et al. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.04.022 · Cited by 63
Self-citationJones, C. W., Keil, L. G., Weaver, M. A., & Platts-Mills, T. F. (2014) · Systematic Reviews · doi:10.1186/2046-4053-3-126 · Cited by 61
Govinden, G., Parker, J. L., Naylor, K. L., Frey, A. M., Anumba, D. O. C., & Stafford, G. P. (2018) · Archives of Microbiology · doi:10.1007/s00203-018-1520-4 · Cited by 42
Ide, K., Yamada, H., Matsushita, K., Ito, M., Nojiri, K., Toyoizumi, K., Matsumoto, K., & Sameshima, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096373 · Cited by 37
Yuan, Y., Wang, R.-T., Xia, J., & Cao, H.-J. (2021) · Journal of Integrative Medicine · doi:10.1016/j.joim.2021.09.001 · Cited by 15
Metadata
- Authors
- Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Heneghan, C. J., Hama, R., & Thompson, M. J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2012-01-18
- Volume
- 1
- Pages
- CD008965-CD008965
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2412668936
- Cited by
- 594
- References
- 161
- Type
- reference entry
- Language
- en
- Update notices
- new_version (2014-04-10)
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.